Human Antibodies To Pcsk9 For Use In Methods Of Treating Particular Groups Of Subjects

Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9 specific antibodies or antigen binding fragments thereof and preferably by additional administration of an inhibitor of 3 hydroxy 3 methyl glutaryl CoA reductase (HMG CoA reductase). The present invention further relates to PCSK9 specific antibodies or antigen binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material PCSK9 specific antibodies or antigen binding fragments thereof and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments which groups of patients must not be treated with said antibodies or fragments and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9 specific antibodies or antigen binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub groups of patients.

Patent Information

Applicants

Inventors

Specification

Documents

Application Documents